We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-2.95%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$333M
Cap. Flow
-$249M
Cap. Flow %
-22.11%
Top 10 Hldgs %
64.02%
Holding
82
New
15
Increased
14
Reduced
31
Closed
17

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$16.3M
2
BRKR icon
Bruker
BRKR
+$13.9M
3
TFX icon
Teleflex
TFX
+$12.7M
4
PCVX icon
Vaxcyte
PCVX
+$12.7M
5
EW icon
Edwards Lifesciences
EW
+$11.9M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$79.5M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$64.4M
3
UTHR icon
United Therapeutics
UTHR
+$32.1M
4
TECH icon
Bio-Techne
TECH
+$26.7M
5
CYH icon
Community Health Systems
CYH
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
2 Miscellaneous 13.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
26
Vaxcyte
PCVX
$8.9B
$10.4M 0.93%
+127,588
New +$12.7M
TVTX icon
27
Travere Therapeutics
TVTX
$6.19B
$8.54M 0.76%
490,296
-379,617
-44% -$6.71M
CYH icon
28
Community Health Systems
CYH
$413M
$8.45M 0.75%
2,827,000
-5,949,455
-68% -$25M
GH icon
29
Guardant Health
GH
$21.7B
$8.43M 0.75%
+276,036
New +$7.77M
RGEN icon
30
Repligen
RGEN
$9.95B
$7.78M 0.69%
54,066
-109,527
-67% -$15.7M
IONS icon
31
Ionis Pharmaceuticals
IONS
$10.1B
$7.51M 0.67%
214,952
-256,403
-54% -$9.58M
FTRE icon
32
Fortrea Holdings
FTRE
$1.79B
$7.49M 0.67%
401,733
-56,234
-12% -$1.1M
NAMS icon
33
NewAmsterdam Pharma
NAMS
$3.1B
$7.08M 0.63%
275,362
-31,995
-10% -$680K
AZN icon
34
AstraZeneca
AZN
$252B
$6.73M 0.6%
+51,331
New +$7.19M
LQDA icon
35
Liquidia Corp
LQDA
$6.06B
$6.72M 0.6%
571,305
+433,356
+314% +$4.74M
MEDP icon
36
Medpace
MEDP
$16.8B
$6.33M 0.56%
+19,049
New +$6.46M
XENE icon
37
Xenon Pharmaceuticals
XENE
$5.81B
$6.1M 0.54%
+155,540
New +$6.43M
MNKD icon
38
MannKind Corp
MNKD
$1.27B
$5.86M 0.52%
911,025
-1,081,479
-54% -$7.25M
HUM icon
39
Humana
HUM
$46.3B
$5.75M 0.51%
22,682
-11,178
-33% -$3M
HSIC icon
40
Henry Schein
HSIC
$9.98B
$5.56M 0.49%
+80,303
New +$5.77M
DHR icon
41
Danaher
DHR
$152B
$5.1M 0.45%
22,209
-16,220
-42% -$3.99M
SNDX icon
42
Syndax Pharmaceuticals
SNDX
$1.74B
$4.54M 0.4%
343,400
-3,761,913
-92% -$64.4M
PDCO
43
DELISTED
Patterson Companies, Inc.
PDCO
$4.51M 0.4%
+146,051
New +$3.39M
GOSS icon
44
Gossamer Bio
GOSS
$83.2M
$4.5M 0.4%
4,978,458
– –
EOLS icon
45
Evolus
EOLS
$587M
$4.23M 0.38%
383,045
-70,016
-15% -$985K
ICLR icon
46
Icon
ICLR
$13.1B
$4.04M 0.36%
19,252
+5,584
+41% +$1.3M
SUPN icon
47
Supernus Pharmaceuticals
SUPN
$2.54B
$3.82M 0.34%
+105,581
New +$3.72M
AVTR icon
48
Avantor
AVTR
$9.86B
$3.55M 0.31%
168,369
– –
PBYI icon
49
Puma Biotechnology
PBYI
$468M
$3.04M 0.27%
996,102
-297,155
-23% -$865K
TSVT
50
DELISTED
2seventy bio
TSVT
$2.95M 0.26%
1,003,678
+5,599
+0.6% +$23K
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Eversept Partners held 82 positions worth $1.13B, down 23% from $1.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Eversept Partners withdrew a net $249M in Q4 2024, closing 17 positions and reducing 31 holdings. Its most notable exit was Insmed, an estimated $79.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Bruker worth $13.8M.

  • Eversept Partners's largest Q4 2024 buy was Bruker: 234,934 shares worth $13.8M.
  • Eversept Partners added most to HCA Healthcare in Q4 2024, an estimated $16.3M increase.
  • Eversept Partners's biggest Q4 2024 reduction was Syndax Pharmaceuticals, cutting an estimated $64.4M.
  • Eversept Partners fully exited Insmed in Q4 2024, selling an estimated $79.5M.
  • Eversept Partners's ten largest holdings make up 64% of its $1.13B portfolio in Q4 2024.
  • Eversept Partners opened 15 new positions and closed 17 in Q4 2024.
  • Eversept Partners's portfolio value fell 23% quarter-over-quarter to $1.13B.

Based on Eversept Partners's 13F filing for Q4 2024, filed 14 Feb 2025.